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Review Article

Therapeutic Modulation of Apoptosis: Targeting the BCL-2
Family at the Interface of the Mitochondrial Membrane
Kathleen N. Nemec and Annette R. Khaled
Biomolecular Science Center, Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL 32826, USA.

A vast portion of human disease results when the process
of apoptosis is defective. Disorders resulting from inappropriate
cell death range from autoimmune and neurodegenerative
conditions to heart disease. Conversely, prevention of apoptosis
is the hallmark of cancer and confounds the efficacy of cancer
therapeutics. In the search for optimal targets that would
enable the control of apoptosis, members of the BCL-2 family
of anti- and pro-apoptotic factors have figured prominently.
Development of BCL-2 antisense approaches, small molecules,
and BH3 peptidomimetics has met with both success and
failure. Success-because BCL-2 proteins play essential roles in
apoptosis. Failure-because single targets for drug development
have limited scope. By examining the activity of the BCL-2
proteins in relation to the mitochondrial landscape and
drawing attention to the significant mitochondrial membrane
alterations that ensue during apoptosis, we demonstrate the
need for a broader based multi-disciplinary approach for the
design of novel apoptosis-modulating compounds in the
treatment of human disease.
Key Words: Apoptosis, BAX, BH3, drug design, peptide therapy

FUNDAMENTALS OF APOPTOSIS
Apoptosis or programmed cell death is a fundamental process that is essential for embryonic
development and the maintenance of adult tissue
homeostasis. Apoptosis is also the most common
mechanism by which damaged, infected or
unneeded cells are eliminated without producing
an inflammatory response, as results when damage
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induces necrosis. It is therefore not surprising that
human disease frequently result from dysregulation of the apoptotic process, making this cell
suicide mechanism an effective therapeutic target.
Our understanding of the apoptotic process and
its complex levels of regulation are founded in the
pioneering studies of Horvitz and colleagues who
dissected the cell death pathway in the nematode
Caenorhabditis elegans (C. elgans).1 Their discovery of
two genes, ced-3 and ced-4 (cell death abnormal),
revealed the core machinery required for executing apoptosis in somatic cells. Ced-3 encodes
a gene product that is a member of the caspase
(cysteine-dependent, aspartate-specific) family of
proteases that are responsible for proteolysis and
destruction of key cell components.2 Ced-4 encodes
a gene product that is a scaffolding/adaptor
protein needed for activation of Ced-3.3 Its
mammalian counterpart is Apaf-1 (apoptotic
protease-activating factor-1). The action of Ced-3/
Ced-4 is regulated by a third gene called ced-9.
Ced-9 prevents cell death in C-elegans.4 Lastly, the
discovery of the egl-1 gene (egg, laying defective)
revealed the final regulatory component of the
death machinery in C-elegan.5 The mammalian
counterparts of Ced-9 and Egl-1 belong to the
long-studied, but still poorly understood, BCL-2
(B cell lymphoma) family of apoptotic modulators.
An anti-apoptotic member of the family is the
mammalian counterpart of Ced-9, while a
pro-apoptotic member of the Bcl-2 family is the
mammalian counterpart of Egl-1.

THE BCL-2 FAMILY
BCL-2 was the first human proto-oncogene
Yonsei Med J Vol. 49, No. 5, 2008
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discovered that promoted neoplastic expansion by
inhibiting death.6,7 BCL-2 became the founding
member of a family of anti-apoptotic and proapoptotic proteins that share one to four homology
domains (BCL-2 homology regions BH1-BH4).8-10
Other anti-apoptotic BCL-2 homologues have
been identified, such as BCL-XL11 and MCL-1.12
Two classes of BCL-2 pro-apoptotic members are
known. Of the class of multi-domain proteins,
BAX was the first death-inducing protein identified
as part of the BCL-2 family.13 Other multi-domain
proteins that share structural similarities with
BAX are BAK14,15 and BOK.16 The second class of
BCL-2 pro-apoptotic proteins share a single homology domain - the BH3 domain - which include
17
18
19
20
BAD, BID, BIM, NOXA and PUMA. To date,
over twenty different BCL-2 family members have
been identified.
Ablation, in mice, of the genes encoding
members of the BCL-2 family revealed that despite
functional overlap, these proteins are essential for
normal tissue development and homeostasis.21-23
Over time, a certain progress was made revealing
the mechanisms that regulate the apoptotic
activity of these proteins. Homo- and heterodimerization among BCL-2 family is one means
by which their activity is regulated. The BH3
domain, common to many BCL2 family members,
is integral in this regard.24 Thus BH3-only proteins
can act as sensitizers or activators of anti- and
pro-apoptotic BCL-2 proteins,25 and their specialization is evident in their regulation. A truncated
and active form of BID is produced by caspase
26
8-mediated cleavage.
In contrast, BAD is
phosphorylated by Akt (Protein Kinase B) and
27
then sequestered by 14-3-3. Alternative splicing
generates multiple isoforms of BIM19,28 that are
sequestered by LC8, a component of the dynein
motor complex,29 while Forkhead (FKHR) transcription factors may regulate its synthesis.30
NOXA and PUMA are transcriptionally regulated
by p53.20
Regulation of the apoptotic activity of the multidomain pro-apoptotic BCL-2 family members is
less well understood. BAK is a mitochondrialresident protein whose intramembreanous oligomerization is inhibited by association with the
voltage-dependent anion channel 2 (VDAC2).31
BAX is found as a cytosolic monomer in nonYonsei Med J Vol. 49, No. 5, 2008

apoptotic cells that inserts into the outer mitochondrial membrane (OMM) upon induction of
cell death and leads to the release of cytochrome
c.32,33 Multiple conformation-specific binding
partners have been identified for BAX,34 but their
role in the translocation, oligomerization, or membrane-insertion of BAX remains poorly defined.
Our own studies contributed by demonstrating
that cytokine withdrawal in lymphocytes leads to
the mitochondrial translocation of BAX in parallel
with intracellular alkalinization35 mediated by the
36,37
sodium hydrogen exchanger 1 (NHE1),
and
that BAX deficiency could partially restore
lymphocyte development in cytokine-deficient
mice, demonstrating the importance of BAX in the
38
homeostasis of immune cells. These studies
showed that BAX is indispensable for the
induction of apoptosis, specifically in the immune
system, and suggest that disease could be the
outcome when the activity of this death factor is
deregulated.

APOPTOSIS AND HUMAN DISEASE
A balance between cell death and cell proliferation must be maintained to ensure the health of
every human being. Recent findings indicate that
approximately one-half of all major human diseases
are a consequence of abnormal apoptosis.39
Inappropriate apoptosis can cause autoimmune
and neurodegenerative disorders as well as heart
disease, while resistance to apoptosis can promote
cancer and impede the effectiveness of cancer
therapeutics.
Autoimmune diseases may arise from defective
clearance of autoreactive lymphocytes and problems with the elimination of apoptotic bodies. The
resulting tissue destruction can be devastating.
The BH3-only protein, BIM, may be an essential
mediator in the death of autoreactive lymphocytes,
since loss of BIM prevented the deletion of these
cells.40 Myocardial ischemia and cerebral ischemia
are leading causes of death in the developed
world. In mouse models of these diseases, interference with the activation of BAX or overexpression of BCL-2 prevented apoptosis and
41,42
reduced infarct size,
implicating these proteins
in tissue destruction. BAX itself plays a principal
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role in the death of neurons that cause Parkinson's
disease43 and may contribute to multiple sclerosis44
and autoimmunity.45
Cancer is the result of a succession of genetic
changes that ultimately confer some form of
growth advantage. Resistance to apoptosis is a
fundamental part of carcinogenesis. Almost half of
human cancers contain mutations in the gene for
the tumor suppressor, p53. Multiple BCL-2 family
members, such as BAX, BID, NOXA and PUMA
are upregulated by and responsive to p53.20,46,47
Deregulation of numerous BCL-2 family members
have been detected in diverse cancers, starting
with its founding member BCL-2, discovered as
chromosomal translocation with the immunoglobulin heavy chain locus in non-Hodgkin's
lymphoma, follicular B-cell lymphoma, and
diffuse large cell lymphomas.48,49 Gastrointestinal
tumors and leukemias can have abnormalities in
BAX.50,51 Moreover, mouse models have revealed
that deficiency in BAD,52 inactivation of BIM,53
loss of BAX54 or overexpression of BCL-XL can
underlie myc-induced leukemias or lymphomas,
suggesting that these apoptotic modulators are
significant contributors to the process of carcinogenesis.
Dysregulation of BCL-2 family members also
confer resistance to the cytotoxic effects of cancer
therapeutic agents. For example, in human epithelial
cancers the absence of BAX completely eliminated
death in response to certain chemo-preventive
strategies.55 Therapeutics targeting BCL-2 proteins
must therefore be engineered to not only inhibit
or modify the function of these apoptotic factors
but must also work in concert with the current
modes of treatment to maximize effectiveness.

BH3 MIMETICS: THE GOOD, THE BAD
AND THE UGLY
Of the myriad of signals being transmitted
along the apoptotic network, we have decoded
only the most obvious. It is known that the antiapoptotic proteins, BCL-2 and BCL-XL, inhibit
apoptosis when over-expressed,56,57 that when
cleaved, the BH3-only protein, BID, enhances the
binding of the pro-apoptotic, multidomain protein,
BAX,58 that the oligomerization of BAX and its

counterpart, BAK, are necessary for permeabilization of the OMM,59 that the BH3-only protein,
BIM, enhances but is not required for BAX to
destabilize an engineered membrane60 What is not
known, however, is precisely how these proteins
interact with the membranes of organelles like
mitochondria to inhibit or induce apoptosis,
making the design of modulating compounds a
challenge.
Recent advances in attempting to harness
apoptosis further elucidate the molecular requirements for designing effective peptide mercenaries.
Mimetics of the DNA repair factor, Ku70, yielded
crucial residues for binding to BAX and inhibiting
apoptosis.61 However, as a single target inhibitor
of apoptosis, the Ku70 peptide had a limited
application in preventing cell death by inhibiting
BAX. Conversely, the development of BH3
mimetics, concisely reviewed by Zhang et al,62 is
an attempt to exploit the pro-apoptotic function of
native BH3-only proteins. As example, Goldsmith
et al, using the active helical sequence of BID and
BAD proteins, generated a peptide with an
arginine homo-polymer to make them permeable
to cells.63 These peptidomimetics demonstrated in
vitro and in vivo effectiveness against neuroblastoma
by disrupting the protein-protein interactions
between BCL-2 and endogenous BH3 proteins.
Using a novel approach, Li et al fused the
antennapedia peptide transduction domain
(ANT), to BAX, BAK and BAD BH3 sequences
and tested the peptides against head and neck
squamous cell carcinoma.64 These peptides
demonstrated an improvement over the polyarginine transduction motif. Though promising,
these peptidomimetics target only individual
anti-apoptotic proteins. This is a problem because
not all cancers are alike and thus require
customized therapies. To address this, the single
target limitations of BH3 peptidomimetics was
exploited in concept of BH3 profiling,65 a method
used to identify cancers that are amenable to
specific BH3 peptidomimetics. This was successfully used to identify cancers most responsive to
the small molecule ABT-737.65 BH3 peptidomimetics are thereby most useful, not for direct
induction of apoptosis, but for predicting sensitivities to already developed therapeutic agents.65
The current trend to target the BCL2 family of
Yonsei Med J Vol. 49, No. 5, 2008
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proteins in order to control apoptosis follows
logically from the notion of targeting the first
cause. However, thinking linearly about pathways
in terms of upstream and downstream events not
only limits possible outcomes but confounds data
interpretation as well. The strengths and limitations
of BH3 peptidomimetics are a reflection of the
complexity of the intertwining pathways that
characterize cellular destruction. Wading through
the flood of experimental data relating to
apoptosis, it is becomes evident that apoptosis is
not a linear event, but a network of spatialtemporal events centered about the mitochondria.
The mitochondria cannot be viewed just as
scaffold for crucial cellular processes, or a
reservoir for apoptotic proteins, but rather an
integral part that is at the crossroads of life and
death itself.

THE MITOCHONDRION
In order to understand the apoptotic process
and design novel therapeutic approaches
targeting the BCL-2 family, one must understand
the architecture of the mitochondrion and how the
different BCL-2 proteins interact with this most
unique of organelles. In most cells, mitochondria
are analogous to major metropolitan centers. Like
a macroscopic metropolis, the essential services of
a thriving community converge within the
mitochondria. Here, crucial cellular processes such
as oxidative phosphorylation, lipid metabolism,
and porphyrin and steroid hormone synthesis are
housed. Calcium is transiently stored within the
mitochondrial matrix, enabling the mitochondrion
to function as a signal transduction rheostat. In
addition to its primary function, ATP synthesis
via the citric acid cycle, the mitochondrion
participates in cell cycling, growth and
differentiation. It is not surprising then, that
determinants that lead to the commitment to
apoptosis intersect at the mitochondria.
Like the high density of skyscrapers in an urban
metropolis, the high protein to lipid ratio of the
outer mitochondria membrane (OMM), approximately 1 protein to 45 lipids, leaves very little
membrane surface area exposed. This feature is
critical, and must be taken into consideration,
Yonsei Med J Vol. 49, No. 5, 2008

when designing drugs, small molecules or
peptides that target mitochondria. The skyline of
the mitochondrial surface is dotted with large
protein complexes such as VDAC (voltage
dependent anion selective channel) and signaling
complexes anchored by AKAP121/8466 and TOM
(translocase of the outer membrane) as well as
smaller integral proteins like porins, which form
small diameter pores that are permeable to
molecules no larger than 5kDa. The protein density
of the inner mitochondrial membrane (IMM) is
even greater with approximately 1 protein for 15
lipids, slightly more dense than the OMM. The
phospholipid composition is the same as the
OMM with the exception of the presence of
cardiolipin, an unusual phospholipid that has four
acyl chains and carries two negative charges in its
head-group. The presence of cardiolipin in the
inner membrane makes the IMM nearly impermeable to ions. It requires another energy-driven
protein complex, TIM (translocase of the inner
membrane), to facilitate transport across the IMM.
The unique mitochondrial membranes not only
sequester individual components of mitochondrial
processes, but they also function as integral
elements of those processes. For example, an
electrochemical gradient is set up by the active
translocation of protons out of the matrix, through
the IMM and into the inter-membrane space. Thus
the inner membrane acts as an electronic capacitor
as a result of the asymmetric charge distribution
on either side of that membrane. The energy
potential of the capacitor drives the production of
ATP by protein complexes imbedded in the inner
leaflet of the membrane’s phospholipid bilayer.
The ATP production potential of the mitochondria
is greatly enhanced by the convoluted folding of
the inner membrane into an elaborate labyrinth of
ATP producing niches. The resultant folded
structures are called Cristae and the space in
between the cristae is the mitochondrial matrix,
the storage compartment for ATP. The two
membranes meet at junctions where VDAC and
TOM complexes converge. It is here that the
unique phospholipid, cardiolipin, is found on the
outer leaflet of the inner membrane. Mitochondria
are thus the energy factories of a cell, and it is
therefore not surprising that the same machinery
that gives life is subverted during the apoptotic
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process to cause cell death.

THE MITOCHONDRIAL-DEPENDENT
APOPTOTIC PATHWAY
The two main pathways for apoptosis are
known as the extrinsic or death receptor pathway
and the intrinsic or mitochondria-dependent
pathway. Though both pathways are important,
the intrinsic pathway is most responsive to
external or environmental cues and DNA damage.
The intrinsic apoptotic pathway follows a
prescribed sequence of events that center on the
mitochondria. One of the earliest observable events
is the structural remodeling of mitochondrial
cristae,67 which is followed by the translocation of
cardiolipin from the inner leaflet of the IMM to
the outer leaflet of the OMM.68,69 This translocation is reminiscent of the exposure of
phosphatidyl-serine (PS) and annexin-I from the
intercellular leaflet to the extracellular face of the
plasma membrane. The translocation event
coincides with the cristae junction remodeling
event reported by Zhang et al.70 Cytochrome c, a
highly positively charged heme-containing protein
that is involved in electron transport and oxidative
phosphorylation, is anchored to cardiolipin in the
mitochondrial matrix and presumably translocates
with cardiolipin to the intermembrane space.
Cristae reorganization leads to the disruption of
the mitochondrial inner membrane potential.71
These events are quickly followed by the OMM
permeabilization (MOMP) and release of
mitochondrial proteins from the intermembrane
space, specifically cytochrome c.
Once released, cytochrome c associates with
Apaf-1 and procaspase 9 to form the apoptosome.
Activated caspase 9 is released from the
apoptosome, initiating the caspase cascade. Other
apoptotic factors released from mitochondria
include Smac/DIABLO (second mitochondriaderived activator of caspases/direct IAP-binding
protein with low pI), AIF (apoptosis inducing
factor), EndoG (Endonuclease G), and HtrA2/Omi
(high temperature requirement protein A2). Each
protein has a specific apoptotic function, which is
temporally coordinated by MOMP. For example,
EndoG orchestrates the nuclear condensation and

chromatin (DNA) fragmentation. Apoptosis
culminates with the packaging of cellular contents
into apoptotic bodies that are engulfed by the
cell’s "haz-mat" team, the macrophages. Thus
concludes a series of highly orchestrated events
whose conductors are members of the BCL-2
family, apoptotic proteins whose principal
binding sites are postulated to be in the very
crowded OMM.

THE NEXT STEP: THE MULTI-DISCIPLINE
APPROACH FOR DESIGNING NOVEL
THERAPEUTICS
Returning to the metropolis analogy, targeting
a single type of structure (such as one BCL-2
family member) may or may not initiate the
cascade that demolishes the entire city (or cell).
The consequence of targeting that structure
depends on the number, function and redundancy
of that structure. Rather than targeting the
redundant structures with the intent of setting off
a cascade of events leading to the implosion of the
foundation, perhaps the foundation itself should
be the target. In the case of the BCL-2 family - the
foundation is the mitochondrion. There is
evidence that the mitochondria itself can act
independently of BAX to promote apoptosis
through the disruption of micro-domains72 or
changes in its ultrastructure.73 Additionally, specific
mitochondrial
membrane
components,
for
example cholesterol and sphingomyelin, have
74,75
been implicated as mediators of apoptosis
as
well as the physical properties of those components, such as fluidity and topography.75
In terms of the BCL-2 family, apoptosis-driven
mitochondrial changes can impact upon their
activation. We found that in experiments
combining cytosol, containing transfected-BAX,
and mitochondria, isolated from apoptotic or
non-apoptotic BAX-deficient HCT116 cells, the
predominant fraction of transfected BAX spontaneously translocated to apoptotic mitochondria
(Tschammer et al. unpublished results). This is
shown diagrammatically in Fig. 1, in which the
mitochondrial membrane from apoptotic cells
contains a very different array of proteins and
arrangement of lipids in comparison to nonYonsei Med J Vol. 49, No. 5, 2008
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A

B
Fig. 1. Mitochondrial membranes are sites of dynamic events during apoptosis. (A). In non-apoptotic cells the cytosol
contains monomeric BAX (light red), while in the outer mitochondrial membrane (OMM), membrane-associated BAX
monomers (dark red) are found in close association with anti-apoptotic proteins like BCL-2 (blue-green) or BCL-XL (green).
Membrane-associated BAK (dark red) is found in complex with VDAC2. Soluble BH3-only (lavender) proteins like BAD
or BIM are sequestered by distinct regulatory mechanisms in the cytosol. The mitochondrial cristae junction is denoted by
the two pores that span both mitochondrial membranes. ATP synthesis proteins (pink) are embedded in the inner
mitochondrial membrane (IMM). Cholesterol (yellow) spans both bilayers. Cardiolipin (double red squares) has bound
cytochrome c (dark blue) and together these are located in inner face of the IMM. SMAC/Diablo (light blue smiley faces),
as examples of mitochondrial apoptotic factors, is found in the intermembrane spaces. (B) In apoptotic cells, cardiolipin
(double red squares), flips from the IMM inner leaflet to the OMM outer leaflet, carrying cytochrome c. Initiation of
apoptosis activates cytosolic BAX (light red) which is recruited to the OMM to form oligomers (dark red). This is enabled
by membrane-associated BAX (dark red) and BAK monomers that are no longer sequestered by BCL-2, BCL-XL or VDAC2
and can act as nuclei for the initiation of BAX/BAK oligomer formation. This process is enabled by soluble BH3 proteins
(lavender) that bind to and inactivate BCL-2 (blue-green) and BCL-XL (green). The cristae junction is spanned by BAX/BAK
oligomeric complexes and mitochondrial membrane is disrupted, leading to the release of cytochrome c (dark blue) and
SMAC/Diablo (light blue) into the cytosol.

apoptotic cells. The mitochondrial landscape is
therefore dramatically altered under apoptotic
compared to non-apoptotic conditions. This is an
important consideration when designing therapeutics to modify the activity of the BCL-2
proteins, in particular when designing novel
Yonsei Med J Vol. 49, No. 5, 2008

compounds that produce the similar lethal effects
upon mitochondria without the need for first
identifying specificity (as with the BH3 mimetics).
In the attempt to harness cellular death to cure
disease, it is imperative to keep in mind the final
outcome of the avalanche that is being triggered.

BCL-2 and the Mitochondrial Membrane

The most important difference between damageinduced necrosis and apoptosis is that death by
necrosis triggers an inflammatory immune
response, an unwanted result in ischemic insult
but perhaps a necessary one when total
annihilation of a cancer is desired. Consequently,
the limited, linear perspective of protein-protein
interactions, as has dominated the development of
BH3 peptidomimetics, must be broadened to
include all the permutations of possible contributors from the mitochondrial microenvironment.
This includes not only the large number of protein
complexes crowding the mitochondrial surface
(Fig. 1) but the complexity of the lipids that make
up the membrane milieu as well.
In conclusion, the repertoire of potential
structures in our arsenal must include more than
the hydrophobic alpha helices that have been the
focus of so much study and development. The
contribution of electrostatics, and more importantly lipophilicity, must also be considered in
the development of drugs, small molecules and
peptidomimetics that target components of
mitochondrial-dependent apoptosis in human
diseases. In the field of apoptosis, a large gap is
slowly being bridge between the biological and
physical approaches that rely on knowledge bases
unique to each discipline. Great strides have been
made already and by encouraging the addition of
a biophysical perspective to create an interdisciplinary research base perhaps more of the
missing pieces to the puzzle that is the BCL-2
family will be found.
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